Related Experiment Videos
Comparison of various macrophage-inhibitory agents on vaginal and systemic herpes simplex virus type 2 infections
Abstract:
Pretreatment of mice intraperitoneally with silica, trypan blue, or dextran sulfate to inhibit macrophage function markedly increased the lethality of a systemic intravenous infection with herpes simplex virus type 2, but did not affect the lethality or local virus growth after vaginal infection of mice with herpes simplex virus type 2. Agents which inhibit macrophage function by different mechanisms decreased host resistance to herpes simplex virus type 2, but the effects of macrophage-inhibitory agents may vary according to the route of virus infection.
Insights
Inhibiting macrophage function increased herpes simplex virus type 2 lethality in systemic infections but not vaginal infections in mice. Macrophage inhibition effects on host resistance depend on the virus infection route.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- Herpes simplex virus type 2 (HSV-2) can cause systemic and localized infections.
- Macrophages play a crucial role in the host immune response to viral infections.
Purpose of the Study:
- To investigate the impact of macrophage inhibition on HSV-2 lethality and viral growth.
- To determine if the route of HSV-2 infection influences the effect of macrophage-inhibitory agents.
Main Methods:
- Mice were pretreated with agents (silica, trypan blue, dextran sulfate) to inhibit macrophage function.
- Mice were infected intravenously or vaginally with HSV-2.
- Lethality and local virus growth were monitored.
Main Results:
- Systemic intravenous HSV-2 infection lethality was markedly increased by macrophage inhibition.
- Vaginal HSV-2 infection lethality and local virus growth were not affected by macrophage inhibition.
- Different mechanisms of macrophage inhibition yielded similar outcomes regarding infection route dependency.
Conclusions:
- Macrophage function is critical for host defense against systemic HSV-2 infection.
- The route of HSV-2 infection significantly modulates the impact of macrophage inhibition on disease outcome.
- Targeting macrophage function may have differential therapeutic implications based on the site of HSV-2 infection.